New immunotherapy combo aims to keep deadly childhood cancer from returning
NCT ID NCT03033303
Summary
This study tested whether a combination of immunotherapy drugs (Hu3F8 and GM-CSF) plus a vitamin A-like drug (isotretinoin) could help prevent cancer from coming back in children with high-risk neuroblastoma who had achieved their first remission. The trial involved 59 patients who had already responded well to initial treatment. Researchers wanted to see if this maintenance therapy could extend the time patients remained cancer-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.